Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup.

Published

Journal Article (Review)

Despite substantial investments by government, philanthropic, and commercial sources over the past several decades, traumatic brain injury (TBI) remains an unmet medical need and a major source of disability and mortality in both developed and developing societies. The U.S. Department of Defense neurotrauma research portfolio contains more than 500 research projects funded at more than $700 million and is aimed at developing interventions that mitigate the effects of trauma to the nervous system and lead to improved quality of life outcomes. A key area of this portfolio focuses on the need for effective pharmacological approaches for treating patients with TBI and its associated symptoms. The Neurotrauma Pharmacology Workgroup was established by the U.S. Army Medical Research and Materiel Command (USAMRMC) with the overarching goal of providing a strategic research plan for developing pharmacological treatments that improve clinical outcomes after TBI. To inform this plan, the Workgroup (a) assessed the current state of the science and ongoing research and (b) identified research gaps to inform future development of research priorities for the neurotrauma research portfolio. The Workgroup identified the six most critical research priority areas in the field of pharmacological treatment for persons with TBI. The priority areas represent parallel efforts needed to advance clinical care; each requires independent effort and sufficient investment. These priority areas will help the USAMRMC and other funding agencies strategically guide their research portfolios to ensure the development of effective pharmacological approaches for treating patients with TBI.

Full Text

Duke Authors

Cited Authors

  • Diaz-Arrastia, R; Kochanek, PM; Bergold, P; Kenney, K; Marx, CE; Grimes, CJB; Loh, LTCY; Adam, LTCGE; Oskvig, D; Curley, KC; Salzer, W

Published Date

  • January 15, 2014

Published In

Volume / Issue

  • 31 / 2

Start / End Page

  • 135 - 158

PubMed ID

  • 23968241

Pubmed Central ID

  • 23968241

Electronic International Standard Serial Number (EISSN)

  • 1557-9042

Digital Object Identifier (DOI)

  • 10.1089/neu.2013.3019

Language

  • eng

Conference Location

  • United States